Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 13

Trial Status

Completed3

Role Distribution

Other Roles3

Activity Timeline

Clinical Trials (3)

NCT02597114Phase 1Completed
Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181
Mucopolysaccharidosis I
StudydirectorStart date: 2015-11-01
NCT02371226Phase 1Completed
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
Mucopolysaccharidosis I
StudydirectorStart date: 2015-07-01

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

ArmaGen, Inc

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Lynda Polgreen, MD

The Lundquist Institute at Harbor-UCLA Medical Center

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Chester B. Whitley, M.D., Ph.D.

University of Minnesota

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Tippi C MacKenzie, MD

University of California, San Francisco

Moderately Similar
2 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Lynda E Polgreen, MD, MS

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Moderately Similar
2 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Markus Ries, MD PhD MHSc FCP

markus.ries@med.uni-heidelberg.de

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Thomas JA Lehman, MD

Chief, Division of Pediatric Rheumatology, Hospital for Special Surgery; Professor of Clinical Pediatrics, Cornell University

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Ashley Schneider

University of Minnesota

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Paul Harmatz, M.D.

Oakland Children's Hospital

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Thierry BILLETTE DE VILLEMEUR

INSERM UMR 1141

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Heather Lau, M.D.

New York University

Moderately Similar
1 trials

Shared therapeutic areas:

Mucopolysaccharidosis IMucopolysaccharidosis II
Similarity Score30%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT02597114Phase 1StudyDirector

Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181

Mucopolysaccharidosis I
Completed
NCT02371226Phase 1StudyDirector

Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I

Mucopolysaccharidosis I
Completed
NCT02262338Phase 1StudyDirector

Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome

Mucopolysaccharidosis II
Completed

All 3 trials loaded